Up 14% in a month, is the Resmed share price just getting started?

The sleep apnoea and respiratory company's shares have had a fine start to FY23.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Resmed shares have pushed higher in the new financial year
  • Healthcare has proven to be a defensive sector in these volatile times
  • In the past 12 months, the Resmed share price is down almost 6%

The ResMed Inc (ASX: RMD) share price has been a solid gainer this past month of trade, up almost 14% in that time.

The company's shares have travelled from a low of $27.63 apiece on 25 May to their current price of $32.34 a share.

Meanwhile, healthcare shares are rebounding in June-July, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 13% in a month as well. The year-to-date performances of both Resmed and the index are charted below:

TradingView Chart

Has the Resmed share price got more?

The broker Morgans is bullish on the Resmed share price and has a price target of $37.95.

In a recent note, the broker said its long-term view on the healthcare player is positive, despite market volatility.

It made note of Resmed's digital platform that addresses kinks along the "healthcare value chain" in its assessment.

Meanwhile, 64% of brokers rate Resmed as a buy right now, according to Refinitiv Eikon data. The remainder say it's a hold, with no sell ratings on the share.

The consensus price target from this list is $33.93, a fraction above its current share price.

Sector-wise, healthcare shares could catch further bids in FY23 if recent trends prevail.

Researchers at Deloitte recently noted a number of catalysts are pushing the "clinical, financial, and operational transformation" of health care – COVID-19 potentially being one of these.

Moreover, the sector is projected to deliver an average earnings per share (EPS) growth of 30% in the second half of CY2022, according to Bloomberg data.

In the past 12 months, the Resmed share price is down 5.7%, falling just over 9% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists analysing results on a computer screen.
Healthcare Shares

3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

After slumping to a 9-year low on 3 June, healthcare shares have rallied by an extraordinary 42%.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Are CSL shares still cheap after almost doubling since June?

The healthcare giant is no longer dirt cheap, but let's find out if the current valuation leaves room for long-term…

Read more »

Buy the dip written on a yellow sign.
Broker Notes

Down 43%! 4 reasons to buy the BIG dip in Pro Medicus shares today

A leading expert believes Pro Medicus shares are well-place to rebound.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL led the ASX healthcare shares rebound. Can it continue?

The rebound of healthcare stocks looks promising, but proving the recovery is real remains.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Ingenia Communities Group rejects takeover offer, backs growth strategy

Ingenia Communities Group has rejected a takeover offer from Warburg Pincus, reaffirming its strategy and Peet acquisition plans.

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Healthcare Shares

CSL shares are up 94% from their low. What are brokers forecasting next?

Can CSL’s improving fundamentals justify the optimism now priced into shares?

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Dividend Investing

Looking to bank the upcoming CSL dividend? You better hurry!

Not only have CSL shares surged 91% since June, but the final dividend payout is still up for grabs. Though…

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Top 3 ASX healthcare shares to buy after a brutal year

Three very different ways to back healthcare.

Read more »